Dose escalation and expansion study of SAR443216 in participants with relapsed/refractory HER2 expressing solid tumors

Trial Identifier: TED16925
Sponsor: Sanofi
Start Date: August 2021
Primary Completion Date: January 2024
Study Completion Date: January 2024
Condition: Cancer - Other; Breast Cancer; Gastric Cancer; Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BELGIUM Gent, BELGIUM, 9000
FRANCE PIERRE BENITE, FRANCE, 69495
FRANCE Villejuif, FRANCE, 94800
KOREA, REPUBLIC OF, Seoul-teukbyeolsi Seoul, Seoul-teukbyeolsi, KOREA, REPUBLIC OF, 05505
KOREA, REPUBLIC OF, Seoul-teukbyeolsi Seoul, Seoul-teukbyeolsi, KOREA, REPUBLIC OF, 03080
SPAIN, Barcelona [Barcelona] Barcelona, Barcelona [Barcelona], SPAIN, 08035
SPAIN, Madrid, Comunidad de madrid, Madrid, Comunidad de, SPAIN, 28040
SPAIN, Madrid, Comunidad de Madrid / Madrid, Madrid, Comunidad de, SPAIN, 28050
TAIWAN, PROVINCE OF CHINA Taichung City, TAIWAN, PROVINCE OF CHINA, 404
TAIWAN, PROVINCE OF CHINA Tainan, TAIWAN, PROVINCE OF CHINA, 704
UNITED STATES, Texas Houston, Texas, UNITED STATES, 77030